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1. Introduction 
 Over the past 30 years, as the expenses and complications involved in 
marketing a new drug entities have increased, with concomitant recognition of the 
therapeutic advantages of controlled drug delivery, greater attention has focused on 
development of sustained or controlled release drug delivery systems. The 
attractiveness of these dosage forms is due to awareness to toxicity and 
ineffectiveness of drugs when administered or applied by conventional method in 
the form of tablets, capsules, injectables, ointments etc. Usually conventional dosage 
form produce wide ranging fluctuation in drug concentration in the blood stream and 
tissues with consequent undesirable toxicity and poor efficiency. These factors such 
as repetitive dosing and unpredictable absorption led to the concept of controlled 
drug delivery systems. 
         The goal of designing sustained or controlled drug delivery systems is to 
reduce the frequency of the dosing or to increase effectiveness of the drug by 
localization at the site of action, reducing the dose required or providing uniform 
drug delivery.1 
1.1  Oral drug delivery:2  
 This is the most widely utilized route of administration among all the routes 
that have been explored for systemic delivery of drugs via different dosage forms. 
Oral route is considered most natural, uncomplicated, convenient and safe due to its 
ease of administration, patient acceptance and cost effective manufacturing process.  
 For the past decades, there has been enhanced demand for patient 
compliance dosage forms. As a result the demand for the technologies has been 
increased three fold annually. Since the development cost of new chemical entity is 
very high, the pharmaceutical companies are focusing on the development of new 
drug delivery systems for existing drug with an improved efficacy and 
bioavailability together with reduced dosing frequency to minimize the side effects. 
1 
 Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
and development of new drug entities, pharmaceutical formulations, mainly because 
of patient acceptance and convenience in administration. It has wide acceptance up 
to 50-60% of total dosage forms. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self medication, pain avoidance and most 
importantly patient compliance. The most popular solid dosage forms are tablets and 
capsules. But the important drawback of these dosage forms is difficult to solve. 
1.2  Modified Drug Delivery system:3  
 Dosage forms can be designed to modify the release of drug over a given 
time or after the dosage form reaches the required location. Drug release acquire 
only after sometime of the administration or for a prolonged period of time or to a 
specific target in the body. Modifications in drug release are often desirable to 
increase the stability, safety and efficacy of the drug, to improve the therapeutic 
outcome of the drug treatment or to increase patient compliance and convenience of 
administration. 
1.2.1  Physicochemical properties of the drug:4 
 Several physicochemical properties of the active drug can influence the 
choice of dosage form. This include aqueous solubility and stability, partition 
coefficient (or, more appropriately, permeability values) and salt form. The aqueous 
solubility and intestinal permeability of drug compounds are of paramount 
importance. A classification has been made whereby drugs can be considered to 
belong to one of four categories: 
• High solubility and high permeability (best case) 
• Low solubility and high permeability 
•  High solubility and low permeability 
• Low solubility and low permeability (worst case). 
2 
 This is now codified as the Biopharmaceutical Classification. Consider first 
the influence of solubility. A drug that is highly soluble at intestinal pH and 
absorbed by passive diffusion (i.e. not site-specific absorption) would probably 
present the ideal properties for inclusion in a modified release dosage form. 
 Drug compounds that satisfy the solubility and permeability requirements 
should also ideally have: 
 A biological half-life of between two and six hours so that 
accumulation in the body does not occur a lack of capability to form 
pharmacologically active metabolites by, for example; first-pass 
metabolism.  
 Modified release is actually used for drugs, which undergo first-pass 
metabolism but this should not be to such an extent that only inactive 
metabolites are left after absorption. 
 A dosage not exceeding 125-325 mg in order to limit the size of the 
delivery system. 
 The factors that influence the rate and extent of absorption depend 
upon the route of administration the intravenous route offers direct 
access to the systemic circulation and the total dose administered via 
this route is available in the plasma for distribution into other body 
tissues and the site(s) of action of the drug. Other routes will require 
an absorption step before the drug reaches the systemic circulation. 
Factors affecting this absorption will depend on the physiology of the 
administration site(s) and the membrane barriers present at those 
site(s) that the drug needs to cross in order to reach the systemic 
circulation. 
 
 
3 
1.2.2 Biopharmaceutical principles of drug delivery:5 
 The Rate and extent of drug absorption into the systemic circulation, a 
schematic illustration of the steps involved in the release and absorption of a drug 
from a tablet dosage form. It can be seen from this that the rate and extent of 
appearance of intact drug in the systemic circulation depends on a succession of 
kinetic processes. The slowest step in this series, which is known as the rate-limiting 
step controls the overall rate and extent of appearance of intact drug in the systemic 
circulation. The particular rate-limiting step will vary from drug to drug. For a drug, 
which has a very poor aqueous solubility the rate at which it dissolves in the 
gastrointestinal fluids is often the slowest step, and the bioavailability of that drug is 
said to be dissolution-rate limited.  
 In contrast, for a drug that has a high aqueous solubility its dissolution will 
be rapid and the rate at which the drug crosses the gastrointestinal membrane may be 
the rate-limiting step (permeability limited). Other potential rate-limiting steps 
include the rate of release of the drug from the dosage form (this can be by design in 
the case of controlled- release dosage forms), the rate at which the stomach empties 
the drug into the small intestine, the rate at which the drug is metabolized by 
enzymes in the intestinal mucosal cells during its passage through them into the 
mesenteric blood vessels, and the rate of metabolism of drug during its initial 
passage through the liver, often termed the 'first-pass' effect. 
1.3    Classification of Modified Release Drug Delivery:6 
 Modified Release dosage form may be classified as 
 Extended release 
 Sustained release 
 Controlled release 
 Delayed release 
 Site specific targeting 
 Receptor targeting 
4 
1.3.1   Extended Release: 
 The term controlled/extended release implies a system that provides 
continuous delivery of the drug for a predetermined period with predictable and 
reproducible kinetics and a known mechanism of release. This means that the 
release of drug  from a controlled release drug delivery system proceeds at a rate 
that is not only predictable  kinetically but also reproducible from one unit to 
another. In other words, the system attempts to control drug concentration in the 
target tissue. 
 The oral route of administration for extended release systems has received 
greater attention because of more flexibility in dosage form design. The design of 
oral extended release delivery systems is subjected to several interrelated variables 
of considerable importance such as type of delivery system, the disease being 
treated, the patient, the length of therapy and the properties of the drug. 
 Extended release denotes that the system is able to provide some actual 
therapeutic control whether be it of temporal or spatial nature or both. In other 
words, the system attempts to provide a constant drug concentration in the target 
tissue. 
 
Fig 1: Plasma level versus time profile showing difference between controlled 
release, sustained release and release from conventional dosage forms.        
5 
1.3.2    Advantages of Extended Release Dosage forms:7 
• Improved patient compliance and convenience due to less frequent 
drug administration. 
• Reduction in fluctuation in steady state levels and therefore, better 
control of disease condition and reduction intensity of local or 
systemic side effects. 
• Increased safety margin of high potency drugs due to better control 
of plasma levels. 
• Maximum utilization of drug enabling reduction in total amount of 
dose administered. 
• Reduction in health care costs through improved therapy, shorter 
treatment period, less frequent dosing and reduction in personnel time 
to dispense, administer and monitor patients. 
• Attenuation of adverse effect, the use of extended release products 
avoids the high initial   blood concentration, which may cause many 
side effects like nausea, local irritation, hemodynamic changes etc. 
1.3.3  Disadvantages of Extended Release Dosage form: 
• Toxicity due to dose dumping. 
• Increased cost. 
• Unpredictable and often poor in vitro- in vivo correlation. 
• Risk of side effects or toxicity upon fast release of contained drug 
(mechanical failure, chewing or masticating, alcohol intake). 
6 
• Local irritation or damage of epithelial lining (lodging of dosage 
forms). 
• Need for additional patient education and counseling. 
• Increased potential for first-pass clearance. 
1.3.4  Ideal candidate for Extended/controlled Release Drug Delivery systems:8  
 The desired biopharmaceutical characteristics of drugs to be used in the 
development of oral controlled release dosage forms are:  
Table 1: Parameters for drug selection 
Parameters for drug selection 
Parameter Preferred value 
Molecular weight <1000 
Solubility >0.1mg/ml for pH 1to pH7.8 
Apparent partition coefficient High 
Absorption mechanism Diffusion 
General absorbability From all GI segments 
Release 
Should not be influenced by pH and 
enzymes 
 
Less protein binding 
 To evaluate whether a drug is viable candidate or not for the design of per 
oral CR formulation, one must consider the following pharmacokinetic parameters 
of the drug. 
Elimination half-life     :  Preferably between 0.5& 8 hours 
Total body clearance    : Should not be dose dependent 
7 
Absolute bioavailability : Should be 75% or more 
Absorption rate               :     Must be greater than release rate 
Therapeutic concentration   :       
 The lower the cssav and the smaller the vd ,the lesser is the amount required. 
Apparent volume of distribution (Vd): 
 The larger the vd and Minimum Effective Concentration (MEC), the larger 
will be the dose size required. The maximum dose to be incorporated in to a per oral 
Controlled release (CR) formulations is about 500mg. The smaller the vd, the easier 
is incorporation of drug in to dosage form.  
Minimum toxic concentration (MTC):       
 Apart the values of MTC and MEC, safer the dosage form and also suitable 
for drugs with very short t1/2. 
1.3.5 Factors influencing oral extended release dosage design:9  
1.3.5.1  Biological Factors 
A. Biological Half Life: 
 The usual goal of an oral extended release product is to maintain 
therapeutic blood levels over an extended period. Therapeutic compounds with short 
half-lives are excellent candidates for sustained release preparation, since this can 
reduce dosing frequency. However this is limited. In general, drugs with half-lives 
shorter than 2 hrs, such as furosemide or levodopa are most candidates for sustained 
release preparations. Compounds with long half-lives, more than 8hrs are also 
generally not used in sustained release forms, since their effect is already sustained. 
Digitoxin, warfarin, and phenytoin are some examples. 
 
8 
B. Absorption: 
 The characteristic of absorption of a drug can greatly affect its suitability as 
a extended-release product. Since the purpose of forming an extended- release 
product is to place control on the delivery system, it is necessary that the rate of 
release is much slower than the rate of absorption. If we assume that the transit time 
of most drugs and devices in the absorptive areas of GI tract is about 8-12hrs, the 
maximum half-life for absorption should be approximately 3-4hrs;otherwise,the 
device will pass out of the potential region before absorption is complete. If a drug is 
absorbed by active transport or transport is limited to a specific region of the 
intestine, sustained release preparations may be disadvantageous to absorptions. 
C. Metabolism: 
 Drugs that are significantly metabolized before absorption, either in the 
lumen or the tissue of the intestine can show decreased bioavailability from slower 
releasing dosage forms. Eg, Aloprenol was most extensively metabolized in the 
intestinal wall when given as a sustained release preparation. High concentration of 
dopa-decarboxylase in a intestinal wall will result in a similar effect for levodopa. If 
levodopa is formulated in a dosage form with a drug compound that can inhibit the 
dopa-carboxylase enzyme, the amount of levodopa available for absorption increase 
and can sustain its therapeutic effects. Formulation of these enzymatic ally 
susceptible compounds as prod rugs is another viable solution. 
1.3.5.2  Physiochemical Factors Influencing Oral Extended-Release Dosage 
Form Design:10 
A. Dose size: 
 For orally administered system, there is an upper limit to the bulk size of 
the dose to be administered. In general, a single dose of 0.5-1.0gm is considered 
maximal for the conventional dosage form. This also holds for sustained –release 
dosage form, those compound that require a large dosing size can sometimes can be 
given in multiple amounts or formulated into liquid systems. Another consideration 
9 
is the margin of safety involved in administration of large amounts of drug with 
narrow therapeutic range. 
B. Ionization, pKa and Aqueous Solubility: 
 Most drugs are weak acids or bases. Since the unchanged form of drug 
preferentially permeates across lipid membrane, the drug in an unchanged form is 
advantageous for drug permeation. Consider a drug for which the highest solubility 
is in the stomach and is unchanged in the intestine. For conventional dosage form, 
the drug can generally fully dissolve in the stomach and then be absorbed in the 
alkaline pH of intestine. For dissolution or diffusion sustaining forms, much of the 
drug will arrive in the small intestine in solid form meaning that the solubility of the 
drug may change several orders of magnitude during its release. Compounds with 
very low solubility (<0.01 mg/ml) are inherently sustained. The drugs that are 
limited in absorption by the dissolution rate are digoxin, griseofulvin and 
salicylamide. The lower limit has been reported to be 0.1mg/ml. 
C. Partition coefficient: 
 When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect these membranes are lipid in 
nature .Therefore, the partition coefficient of oil-soluble drugs becomes important in 
determining the effectiveness of membrane barrier penetration. Partition coefficient 
is generally defined as the ratio of the fraction of drug in an oil phase to that of an 
adjacent aqueous phase. Compounds with a relatively high partition coefficient are 
predominantly lipid soluble and consequently, have very low aqueous solubility. 
Phenothiazine are representative of this type of compound. 
D. Stability: 
 Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. For drugs that are unstable in the stomach, systems prolong 
delivery over the entire course of transit in the GI tract are beneficial. Compounds 
that are unstable in the small intestine may demonstrate decreased bioavailability 
10 
when administered from a sustaining dosage forms. This is because more drugs is 
delivered in the small intestine and hence it is subject to degradation. Propantheline, 
probanthine are representative examples of such drugs. 
1.3.6 Unsuitable candidates for Extended-Release dosage forms: 
 Short elimination biological half-life (< 2hrs).E.g. penicillin G, Furosemide 
 Long elimination biological half-life (>12hrs).Eg; Diazepam, Phenytoin 
 Narrow therapeutic index. Eg; Phenobarbital, Digitoxin 
 Not effectively absorbed in the lower intestine Eg; Riboflavin, Ferrous salts 
 Large dose (>1g) Eg; Sulphonamides. 
1.4 Types of tablet manufacturing:11  
Granulation:  
1.4.1  Wet granulation: 
 Wet granulation involves addition of solution to blended powder and 
mixing is done at a predetermined period of time and at specified speed. After this 
process is complete, the wet mass is milled and dried on a tray drier on to which the 
mass is spread. 
1.4.2  Dry granulation: 
 Dry granulation involves (roll compaction or slugging) involves the 
compaction of powders at high pressures into large, often poorly formed tablets or 
compacts. These compacts are then milled and screed to form a granulation of the 
desired particle size. The advantage of dry granulation is the elimination of heat and 
moisture in the processing. Dry granulation can be produced by extruding powders 
between hydraulically-operated rollers to produce thin cakes that are subsequently 
screed or milled to give the desired granule size. 
11 
1.4.3  Direct compression: 
 Direct compression is used when a group of ingredients are to be blended 
and placed onto a tablet press to be made into a perfect tablet without changing any 
of the ingredients. Powders that can be blended and compressed are commonly 
referred to as directly compressible or as direct-blend formulations. 
1.5  Methods to retard the drug release12 
 It can be classified as follows: 
• Reservoir system including 
 Enteric coated tablets, capsules, coated granules and microcapsules. 
• Osmotic systems 
• Ion-exchange resins 
• Matrix systems 
1.5.1 Matrix Systems 
Definitions: 
  Matrix formulations are defined as a drug or other active ingredient 
embedded in insoluble excipient in order to achieve release by a continuous leaching 
of the drug from the inert matrix core. 
Drug release from the bulk of matrix involves two matrix mechanisms: 
1)  The Erosion rate of the matrix determines the drug release state in 
matrices governed by erosion or dissolution. 
2) The diffusion through a barrier membrane describes drug release in 
insoluble coating via fick’s second law of diffusion. 
12 
                      Table 2: Materials used as retardants in matrix Tablets 
Nature of the polymer Examples 
Insoluble, Inert 
 
Poly Ethylene, Polyvinylchloride, Ethyl Cellulose 
and Methyl acrylate 
Insoluble, Erodible 
 
Carnaubawax,Stearylalcohol,Stearicacid, 
Polyethylene Glycol and Triglycerides. 
Hydrophilic 
Methyl Cellulose, Hydroxy Ethyl Cellulose 
Hydroxy propyl Methyl Cellulose, Xanthan gum, 
Sodium alginate and Chitosan. 
 
1.5.2 Drug Release from Matrix Systems:13 
Mechanism of drug release from swelling controlled release systems 
Polymer swelling and drug release: 
 The overall drug release mechanism from swelling controlled release 
systems based pharmaceutical devices strongly depends on the design (composition 
and geometry) of the particular delivery system. When a matrix comes in contact 
with an aqueous solution, wetting occurs first at the surface and then progresses by 
way of microscopic pore spaces into the matrix.  
 The excipient in the matrix also absorb water, hydrates and swells to block 
up the existing pores, dissolves the content to create a more porous structure, gels to 
form a more viscous solution giving rise to positive pressure opposing liquid entry 
or causes disintegration of the matrix . Before a liquid can enter a matrix, there must 
be a driving force, which is derived from the pressure difference. The rate of liquid 
penetration into the matrix is determined by balance of this force promoting fluid 
entry towards the interior and the viscous force opposing it, which soon develops as 
soluble excipients in matrix dissolve or swell. 
13 
 Fig 2: (a) Drug release controlled by polymer erosion; (b) Drug release 
controlled by swelling and erosion 
 The swelling of the matrix and consequent drug release by diffusion from 
the matrix and erosion of the matrix is shown in Figure 2a and 2b. 
 A hydrophilic matrix, controlled-release system is a dynamic one involving 
polymer wetting, polymer hydration, gel formation, swelling, and polymer 
dissolution. At the same time, other soluble excipients or drugs will also wet, 
dissolve, and diffuse out of the matrix while insoluble materials will be held in place 
until the surrounding polymer/excipient/drug complex erodes or dissolves away. The 
mechanisms by which drug release is controlled in matrix tablets are dependent on 
many variables. The main principle is that the water-soluble polymer, present 
throughout the tablet, hydrates on the outer tablet surface to form a gel layer       
(Fig: 3). Throughout the life of the ingested tablet, the rate of drug release is 
determined by diffusion (if soluble) through the gel and by the rate of tablet 
erosion.14 
 
 
14 
 Fig 3: Mechanism of drug release from matrix gel forming tablets 
1.6  Pharmaceutical coating processes:15  
 Basically  there  are  five  major  techniques  for  applying  coatings  to  
pharmaceutical solid  dosage  forms:  
1.  Sugar coating 
2.  Film coating 
3.  Enteric coating 
4.  Fluid bed or suspension coating 
5.  Compression coating 
1.6.1 Film coating 
 Film coating is a process that involves the deposition of thin but uniform, 
polymer film onto the surface of the core tablet. The polymeric substance most 
15 
commonly used is Hydroxyl Propyl Methyl Cellulose, Hydroxyl Ethyl Cellulose. 
The film coating protects the medicament from the atmospheric effects. By its 
composition the coating is designed to rupture & expose the core tablet at the 
desired location within GIT. 
1.6.2 Advantages 
 Minimal weight increase (typical 2 to 3% of tablet core weight) 
 Significant reduction in processing times 
 Increased process efficiency and output 
 Increased flexibility in formulation 
 Cost effectiveness 
 Acceptable  for diabetic patients     
Table 3: Reasons for Film coating 
Appearance To change the color, for branding purposes. 
Stability 
To protect the active ingredient from moisture, light 
and/or the acidic environment of the stomach 
Taste/odor masking 
To provide an easy to swallow tablet without the 
bitter taste of many actives 
Release 
characteristics 
Many film coating materials have functional 
properties which enable the delayed(enteric)release 
of dosage forms 
 
1.6.3 Components required for film coating formulations: 16 
1.            Polymer: 
 Usually cellulose derivatives, acrylic and copolymers are used. 
16 
 Non enteric polymers: E.g. Hypermellose, HydroxyEthylCellulose, 
polyethylene glycol, Ethyl Cellulose, Hydroxyl propyl Cellulose. 
 Enteric polymer: E.g. Cellulose acetate phthalate, polymethacrylates, 
polyvinyl acetate phthalate. 
2.  Plasticizer: 
 Some of the commonly used plasticizers are castor oil, propylene glycol, 
polysorbates and organic acid   esters. 
3.  Colorants: 
 Colorants are used to provide distinctive color and elegance to a dosage 
form. Colorants can be classified into 3 classes. 
 Organic dyes example: Sunset yellow, Tartrazine, Erythrosine. 
 Inorganic colours example: Iron oxide red, yellow, Titanium dioxide, Talc. 
 Natural colours example:  riboflavin, carmine. 
4.  Solvents: 
 The primary function of a solvent system is to dissolve or disperse the 
polymers and other additives and convey them to the substrate surface. The most 
widely used solvents for enteric coating polymers are water, ethanol, isopropanol, 
chloroform, acetone etc. 
1.7 Hypertension:17 
 Hypertension, or high blood pressure, is a medical condition in which the 
blood pressure is chronically elevated, mainly arterial hypertension. 
 
17 
Hypertension can be classified as 
1.     Essential hypertension indicates that no specific medical cause can be            
found to explain a patient's condition. 
2. Secondary hypertension indicates that the high blood pressure is a 
result of (i.e. secondary to) another condition, such as kidney disease 
or certain tumors (especially of the adrenal gland). 
1.7.1  Blood pressure:   
 It is defined as the lateral pressure exerted by blood on blood vessels. The 
blood pressure which is normally expressed is arterial blood pressure. 
It has two phases: 
1. Systolic blood pressure: it is the maximum blood pressure. This 
 occurs during the systole of the heart (range 100-120mm hg). 
2. Diastolic blood pressure: it is the minimum pressure. It is occurs 
 during the diastole of the heart (range 60-80mm hg). 
Blood pressure ranges: 
 Normal blood pressure          :    Below 120 mm Hg / 80mm Hg 
 Pre hypertension                         :   120-139 mm Hg / 80-89 mm Hg 
 Mild Hypertension (Stage 1)      :   140-159 mm Hg / 90-99 mm Hg  
 Moderate-Severe Hypertension  :   Higher than 160-100 mm Hg 
 The systolic pressure corresponds to the pressure in the arteries as the heart 
contracts and pumps blood forward into the arteries. The diastolic pressure 
represents the pressure in the arteries as the heart relaxes after the contraction. The 
diastolic pressure reflects the lowest pressure to which the arteries are exposed. The 
pressure exerted by blood within the artery is shown in Fig: 4 
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 An elevation of the systolic or diastolic blood pressure increases the risk of 
developing cardiac disease, renal disease, arteriosclerosis, eye damage and stroke. 
These complications of hypertension are often referred to as end-organ damage 
because damage to these organs is the end result of chronic high blood pressure .For 
that reason, the diagnosis of high blood pressure is important so efforts can be made 
to normalize blood pressure and prevent complications. Hypertension is clearly a 
major public health problem. 
 
 
 
 
 
 
 
 
                                   Fig 4: Blood pressure within the artery 
1.7.2  Factors affecting blood pressure:18 
• Blood volume and cardiac output 
• Peripheral resistance 
• Elasticity of blood levels 
• Diameter of lumen of blood vessels 
• Viscosity of blood 
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1.7.3 Mechanism of calcium effect of blood pressure 
 During each heart beat, a relatively small amount of calcium enters inside 
across the sacrolemma during the action potential and more calcium needed for 
muscle activation is released from the sacroplasmic reticulum. This release is 
triggered by calcium influx across the sacrolemma. The intracellular calcium 
concentration increase and brings about muscle contraction (systolic) through 
bridges cycle. Following this calcium is reaccumulated into the sacroplasmic 
reticulum by calcium pumps. This causes relaxation of the muscle (diastole). 
1.7.4 Calcium channel blockers: 
 Calcium channel blockers are class of drugs and natural substances which 
disrupt the conduction of calcium channels. It has effects on many excitable cells of 
the body, like the muscle of the heart, smooth muscles of the vessels or neuron cells. 
The main action of calcium channel blockers is to decrease the blood pressure and is 
mainly prescribed for the treatment of hypertension. Calcium channel blockers 
interfere with the entry of calcium into myocardial and vascular smooth muscle. 
This decreases the availability of intercellular calcium. The three channels of 
calcium transport are: 
1. Voltage dependent channel:  
 It opens and closes in response to a voltage gradient. Calcium channel 
blockers close this gate. This inhibits the entry of extracellular calcium. 
2.  Receptor operated channel:  
 This is activated by alpha adrenergic agonist or angiotensin. This channel 
also blocked by calcium channel blockers. 
3. Sodium channel exchange: 
 It is important only for the action of cardiac glycosides. 
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 Example  of  calcium  channel  blockers  include,  nifedipine (Procardia),  
diltiazem (Cardizem), verapamil (Isoptin,Calan), nicardipine (Cardene), amlodipine 
(Norvasc), and felodipine (Plendil). 
Effect on peripheral blood vessels: 
 Calcium channel blockers relax the vascular smooth muscle in systemic as 
well as pulmonary arterial circulations. The decrease the vascular resistance and the 
blood pressure in both the territories. They have been used with beneficial effect in 
the treatment of  systemic and pulmonary hypertension. 
1.7.5 Important actions of calcium channel blockers are: 
• Antiarrhythmic effect 
• Negative ionotropic effect which decreases cardiac contractility 
• Dilatation of coronary arteries 
• Relaxation of peripheral blood vessels 
• Antianginal effect 
1.7.6 Function of calcium antagonists:19 
• Block calcium entry by preventing opening of voltage-gated L-type 
calcium channels. 
• Mainly affect heart and smooth muscle, inhibiting the calcium entry 
caused by depolarization in these tissues. 
• Selectivity between heart and smooth muscle varies; verapamil is 
relatively cardio selective; felodipine is relatively smooth muscle-
selective, and diltiazem is intermediate. 
• Vasodilator effect is mainly on resistance vessels, reducing after load. 
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• Calcium antagonists dilate coronary vessels, which is important in 
variant angina. 
• Effects on heart (verapamil, diltiazem):antidysrhythmic action(mainly 
atrial tachycardia),because of impaired atrioventricular conduction; 
reduced contractility. 
• Clinical uses 
  Antidysrhythmic (mainly verapamil) 
  Angina (e.g. diltiazem) 
  Hypertension (mainly dihydropyridines) 
1.8 Angina pectoris:  
 Angina is a symptom of a condition is called myocardial ischemia. It occurs 
when the heart muscle (myocardium) doesn’t get as much blood and hence as much 
oxygen as it requires. 
Antianginal property of calcium channel blockers: 
 These drugs are probably due to (1) improvement in the coronary blood 
flow and (2) decrease in the oxygen demand of the heart due to reduction in 
systemic vascular resistance (vasodilatation) and blood pressure (arterial). 
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2. Literature Review 
  
 Hardik Rana et al.,(2013)20, The extended release tablets were 
prepared by direct compression method and formulated using different 
polymer ratios. Hydrophilic polymers like Hydroxypropyl 
methylcellulose K15M (15-35%) and hydrophobic polymer like 
Kollidon SR (10-305%) were used. The results of dissolution studies 
indicated that formulation F2 (KSR-40mg and HPMC-50mg) and F7 
(KSR-60mg and HPMC-30mg) exhibited drug release pattern very 
close to innovator release profile. From that F10 (KSR-50mg and 
HPMC-50mg) was prepared, exhibited same release profile to that of 
innovator product. From the experimental data, an optimal formulation 
was developed which has proved to be similar with the dissolution 
profile of the chosen innovator product and which was protected 
against light and moisture by opadry seal coat and sunset yellow. 
 Zhao Xia.,et al.,(2013),21 To evaluate the bioequivalence of the two 
felodipine extended release tablets in healthy male subjects. Methods A 
single oral dose 5 mg of test and reference felodipine extended release 
tablets were given to 24 subjects according to an open randomized 
crossover design. The concentrations of felodipine in plasma were 
determined by LC-MS/MS. The pharmacokinetic parameters were 
calculated and the bioequivalence was compared. The 90% confidential 
interval of Cmax,AUC0-72h and AUC 0-∞ of tested formulation were 
109.6%~141.6%,99.2%~120.2 % and 96.2%~117.8%. There was no 
statistically significant difference in parameters Tmax between the two 
preparations. The relative bioavailability of felodipine of test 
preparations was (114.0±33.7) %.The two preparations were 
bioequivalent. 
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 Kumar, P. Santhosh; Rao,V.Srinivasa ; et al.,(2012)22A rapid and 
reproducible High Performance Liquid Chromatographic method has 
been developed for the estimation of Felodipine in its pure form as well 
as in pharmaceutical dosage forms. Chromatography was carried out on 
an Symmetry C18 column (25cm × 4.5mm, 5μ), Isocratic elution was 
carried with the mobile phase acetonitrile and water (80:20 v/v) at flow 
rate of 1ml/min. and the detection was done at 234 nm was developed 
and fully validated for the determination of Felodipine. The retention 
time of the drug was 3.617 min. Initially a method was developed and 
partially validated with parameter such as LOD &amp; LOQ, linearity, 
accuracy and precision etc. Results obtained from this study indicates 
that the method is showing perfect linearity in the range of 25 to 200 
μg/ml. LOD and LOQ were found to be 0.125 and 1.25 ng/ml , 
respectively. Our result from the present study also indicates that the 
tested plendil contains 96.6% of Felodipine drug and passed QC 
successfully. 
 Kunal P. Pagar et al.,(2012)23 The research work deals with the 
development of a time delayed chronotherapeutic formulation of 
felodipine (FD) aimed at rapid drug release after a desired lag time in 
the management of hypertension. This dissolution enhancement and 
rapid drug release resulted from FD amorphisation, as confirmed by 
XRD, DSC and SEM studies. FTIR and 1H NMR studies confirmed 
the complex formation between FD and cyclodextrin based on the 
observed hydrogen bond interactions. Influence of formulation 
variables like polymer viscosity, plasticizer concentration, super 
disintegrant concentration in the swellable layer and percent coating 
weight gain was investigated to characterize the lag time. Upon 
permeation of water, the core tablet swelled, resulting in the rupture of 
the coating layer, followed by rapid drug release. The developed 
formulation of FD showed a lag time of 5-7 h, which is desirable for 
chronotherapeutic application. 
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 Hsiao chia-ling et al., (2011)24, The objective of this study was to 
investigate the pharmacokinetics of felodipine in healthy male 
Taiwanese subjects. The subjects received 5 mg (n = 80) or 10 mg (n = 
20) of Plendil® (felodipine extended-release tablets; felodipine ER) 
once daily for 6 days. Compared to data from the literature, the mean 
Cmax, ss and AUCτ of 5 mg felodipine in healthy young Taiwanese 
subjects were similar to or slightly lower than data from Swedish, 
Danish, Turkish and Canadian studies in healthy young subjects who 
received 10 mg felodipine. Comparable Cmax values and approximately 
30% lower AUC values were observed when comparing the 5 mg 
Taiwanese data to data in healthy elderly German subjects who also 
received 5 mg felodipine. Taiwanese subjects might have lower 
CYP3A4 activity to metabolize felodipine, which is similar to the 
phenomenon observed with nifedipine. 
 V.Sreedevi, Puttarajesh kumar et al., (2011)25,The investigation was 
aimed to study bioequivalence of two felodipine formulations and 
pharmacokinetic studies of human plasma were conducted. 
Pharmacokinetic parameters such as Cmax, Tmax, AUC (0-t), AUC(0-
∞), and t½ were calculated and the blood plasma level data of the 
reference product and the test product were compared. Plasma onset of 
drug for both was 0.5 hr. The Cmax for reference product was 10.72 
1.15 ng/ml with Tmax of 3.17 0.7hr. The Cmax and Tmax of the 
Felodipine test product were 10.70 1.17 ng/ml and 3.75 0.44 hr. The 
AUC(0-t) for reference product was 216.24 33.66 ng.h / ml and 196.50 
30.28 ng.h / ml for the test product. Based on the above observations it 
could conclude that the test product is bioequivalent of that of the 
reference product of felodipine and both are well tolerated. Further the 
results of the present investigation shown that there is scope for further 
studies on felodipine metabolism with respect to efficacy and 
pharmacokinetics. 
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 Rares.I, Iovanov,et al.,(2009)26,In this paper we have studied the 
influence of some variables on the release of felodipine from extended 
release hydrophilic matrix tablets. The employed polymers for the 
extension of the release were: hydroxypropyl methyl cellulose 
(Methocel E4MCR and Methocel K100M) and polyethylene oxide 
(PolyoxWSR Coagulant). For this purpose, experimental design with 3 
variables and 2 levels was used. The studied formulation variables 
were: the percent of polymers, the type of hydroxypropyl-
methylcellulose and the ratio between the polymers in the tablet. From 
the obtained results it was concluded that the most important variable 
on the release of felodipine was the percent of polymers in the tablet. 
From the experimental data, an optimal formulation was developed, 
which has proved to be similar with the dissolution profile of the 
chosen reference product. 
 Deepa karthikeyan. M, et al.,(2008)27,In this study, different grades 
of hydroxyl propyl methyl cellulose (HPMC) were used to develop 
floating microspheres of Cefpodoxime Proxetil in order to demonstrate 
the effect of different viscosities on drug release profile. The 
Cefpodoxime Proxetil microspheres were prepared by non aqueous 
solvent evaporation method using different grades of HPMC such as 
HPMC K15M( 15cps), HPMCK4M(4000cps),HPMC100LV(100cps) 
and ethyl cellulose. The prepared microspheres were characterized by 
polymer compatibility (FTIR Scan), percentage yield, Buoyancy 
percentage, Drug Entrapment Efficiency (DEE) and Invitro drug 
release was performed by USP Apparatus type I .The better drug 
release profile was found to be with formulation (FA2 ) with drug: 
polymer ratio of 1:2, HPMC 15cps showed much significant increase in 
the drug release while comparing with the other two grades of HPMC. 
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 Katayoun.,et al,(2008)28,Compared a self-modeling curve resolution 
method was applied to study the photodegradation kinetics of 
nitrendipine and felodipine by spectrophotometric method.It is reported 
that Dihydropyridine are highly photosensitive and converted in the 
presence of light to compounds that are inactive. 
 Porcellati,C.,et al,(2005)29,To assess the duration of the 
antihypertensive effect of the dihydropyridine calcium antagonist 
felodipine in conventional and slow release formulations.12 patients 
with essential hypertension underwent ambulatory blood pressure 
monitoring at the end of a treatment period with C-F 5mg,E-R 10mg 
once daily(o.d.) and placebo.C-F,ER-F, and placebo were given in a 
double-blind 3×3 latin square design 4 times replicated. There was no 
systematic change in the ABP profile over the three study periods 
regardless of the treatment. In comparision to placebo, the mean 24hrs 
systolic and diastolic blood pressures showed a significant and similar 
reduction after both formulations. 
 Kimy, B.K.,et al,(2005)30, prepared Microspheres containing the anti-
hypertension drug, felodipine, by the emulsion solvent evaporation 
method(o/o) using acrylate methacrylate copolymers,Eudragit RL PO 
and Eudragit RS PO, as wall materials. In order to increase the 
encapsulation efficiency, a mixed solvent system comprising 1:1 
proportions of acetonitrile and dichloromethane was used as a 
dispersed phase. The release rate of the Eudragit RS PO microspheres 
was much lower than that of Eudragit RL PO microspheres. Whereas 
Eudragit RL PO microspheres followed the Higuchi rule, Eudragit RS 
PO microspheres exhibited a triphasic release profile. It is concluded 
that drug release rate can be choice of polymer type. 
 Yang.,et al,(2004)31, developed a process for producing an oral 
sustained-release pharmaceutical composition of felodipine is 
discussed. The process includes mixing together felodipine with an 
27 
ionic surfactant, hydrophilic polymer and a release-controlling 
excipient.The pharmaceutical composition of felodipine produced by 
the process enhanced the dissolution rate of insoluble drug of 
felodipine with simultaneously producing pharmaceutical composition 
of felodipine sustained release with superior bioavailability. 
 Pannarale.,et al,(2003)32, Assesed the 24-hr antihypertensive efficacy 
of an extended release 10mg formulation of the dihydropyridine 
felodipine for the treatment of mild-moderate essential hypertension. 
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3. Aim and Objective 
 Hypertension is a major risk for Cardiovascular and stroke complications. 
The good permeability and the poor water solubility (BCS class II) as well as short 
biological half-life characteristics of Felodipine selected as a drug candidate for 
extended release preparations consist 10mg per day tablet preparation. Felodipine 
belongs to dihydropyridine derivative, which acts as a calcium channel blocker, used 
as an anti-hypertensive drug. 
 The aim of the present investigation to develop a once-daily extended 
release dosage form of felodipine in tablet form using different polymer grade in 
varying proportions on to determine which concentration best fit to the desired drug 
profile as per USP. 
 The core and coated tablet to be evaluated, with respect to the physical and 
chemical parameters like hardness, thickness, weight variation, friability, assay 
including Invitro drug release study. The optimized batch to be compared with 
kinetics of drug release, marketed product and similarity, differential factor. 
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4. Plan of Work 
 Preformulation studies 
 Drug Excipient interaction study 
 Bulk density 
 Tapped density  
 Compressibility index 
 Hausner’s ratio 
 Formulation of Felodipine Extended Release tablet by Dry 
 granulation technique. 
 Evaluation of  compressed tablet 
 Hardness 
 Thickness 
 Weight variation 
 Friability 
 Drug content 
 Invitro dissolution study 
 Selection of optimized formula based on Invitro dissolution profile, 
 and film coating of optimized formula. 
 Evaluation of film coated tablet. 
 Average weight  
 Hardness 
 Thickness 
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 Drug content 
 Invitro dissolution study 
 Comparision of optimized formula with marketed product. 
 Release Kinetics. 
 Stability studies of best formulation. 
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5. Drug Profile 
5.1  Felodipine: 33-34 
Category:  
 Antihypertensive (Calcium channel blockers) 
Structure:  
 
Origin of the substance: 
 Felodipine is a dihydropyridine derivative. 
Chemical name: 
 Ethylmethyl4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-    
dimethl3,5pyridinedicarboxylate.   
Molecular formula: C18H19C12NO4 
Molecular weight  : 384.26 
Description          : Felodipine is a slightly yellowish, crystalline powder. Felodipine 
is a racemic mixture. 
Solubility           : It is insoluble in water and is freely soluble in dichloromethane 
and ethanol. 
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Melting point : 142-145˚C 
Pharmacodynamic effects: 
• Felodipine is a vascular selective calcium antagonist, which lowers 
arterial blood pressure by decreasing peripheral vascular resistance.  
• It can be used as monotheraphy or in combination with other 
antihypertensive agents, e.g. β-adrenoceptor blockers, diuretics or 
ACE-inhibitors, in order to achieve an increased antihypertensive 
effect. 
• Felodipine has anti-anginal and anti-ischaemic effects due to 
improved myocardial oxygen supply/demand balance.  
Mechanism of action: 
• Felodipine is a member of the dihydropyridine class of calcium 
channel antagonists (calcium channel blockers).   
• Felodipine decreases arterial smooth muscle contractility and 
subsequent vasoconstriction by inhibiting the influx of calcium ions 
through voltage-gated L-type calcium channels. 
• It reversibly competes with nitrendipine and/or other calcium channel 
blockers for dihydropyridine binding sites, blocks voltage-dependent 
Ca++currents in vascular smooth muscle and blocks potassium-induced 
contracture. 
• Felodipine inhibits electrical and contractile activity of vascular 
smooth muscle cells via an effect on the calcium channels in the cell 
membrane and results in vasodilation. The vasodilatory effects of 
felodipine result in an overall decrease in blood pressure. Felodipine 
may be used to treat mild to moderate essential hypertension. 
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Pharmacokinetics: 
Absorption and Distribution: 
 Following oral administration, felodipine is almost completely absorbed in 
the gastro intestinal tract and undergoes extensive first-pass metabolism. The 
absorption Phase is prolonged. 
Systemic availability     :  20%. 
Plasma protein binding :  99%.  
Volume of distribution :  10 L/Kg 
Biological Half Life      :    14 hrs  
            T max                                             :    2.5 to 5 h.  
 Both peak plasma concentration and the area under the plasma 
concentration time curve (AUC) increase liner with doses up to 20 mg. 
Metabolism and Elimination: 
 Felodipine is extensively metabolized in the liver by cytochrome P450 3A4 
(CYP3A4) and all identified metabolites are inactive. Extensive first pass 
metabolism. 
 About 70% of a given dose is excreted as metabolites in the urine; the 
remaining fraction is excreted in the faeces. Less than 0.5% of a dose is recovered 
unchanged in the urine. 
Uses: 
 Hypertension 
 Angina pectoris 
34 
 Felodipine extended-release tablets may be used alone or concomitantly 
with other antihypertensive agents. 
Therapeutic Dosage :  2.5mg, 5mg, 10mg. 
Posology and method of administration: 
 The tablets should be swallowed with water and must not be divided, 
crushed, or chewed. The tablets can be administered without food or following a 
light meal not rich in fat or carbohydrate. 
Table 4: Brand names& Manufactures 
Brand Names Manufactures 
Plendil Astrazeneca Pharma Limited 
Felodipine Extended release tablet Glenmark generics limited 
Felo ER Mylan Pharmaceuticals 
Felogard Cipla Limited 
Felodipine Extended release tablet Qualitest Pharmaceuticals 
 
Overdose: 
 Over dosage may cause excessive peripheral vasodilatation with marked 
hypotension and sometimes bradycardia. 
Contraindication: 
Pregnancy 
Uncompensated heart failure 
Acute myocardial infarction 
Unstable angina pectoris 
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Drug Interactions: 
Anticonvulsants (eg, barbiturates, carbamazepine, hydantoins) 
 Felodipine plasma concentrations may be reduced in epileptic patients, 
decreasing the therapeutic effects. Alternative therapy should be considered. 
Beta-blockers (eg, metoprolol) 
 Metoprolol plasma levels may be increased. 
CYP3A4 inhibitors (eg, cimetidine, erythromycin, grapefruit juice, 
itraconazole, ketoconazole) 
 Because of an increase in felodipine bioavailability or decrease in 
metabolism, felodipine plasma levels may be elevated several-fold, increasing the 
pharmacologic and adverse effects. 
Histamine H 2 antagonists (eg, cimetidine) 
 Felodipine plasma levels may be elevated, increasing the pharmacologic 
and adverse effects. 
Food Interactions:  
 Grapefruit juice results in increased peak plasma levels and bioavailability 
possibly due to an interaction with flavonoids in the fruit juice.  
Adverse Reactions: 
Cardiovascular  :  Palpitation (at least 1.5%). 
CNS     :  Asthenia, dizziness, headache. 
Dermatologic  :  Flushing, rash.  
EENT    :  Rhinorrhea, sneezing. 
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GI   :  Constipation, dyspepsia, nausea. 
Respiratory  :  Cough, upper respiratory infection. 
Packing and Storage: 
             Store below 30°C (86˚F) .Keep container tightly closed. Protect from light. 
Stability:  
Felodipine is stable under ordinary conditions. 
Excipient Profile 
5.2  Spay Dried Lactose:35 
Nonproprietary Name: 
         None adopted. 
Synonyms: 
 Flow Lac 100; Lacto press Spray-Dried; NF Lactose–316 FastFlo; NF 
Lactose–315; Pharmatose DCL 11; Pharmatose DCL 14;Super-Tab Spray-Dried. 
Structural formula: 
 
  
37 
Chemical Name and CAS Registry Number: 
 It is a mixture of amorphous lactose, which is a 1:1 mixture of a-and-b-
lactose, and O-b-D-galactopyranosyl-(1!4)-a-glucopyranose monohydrate. 
Empirical Formula and Molecular Weight: 
C12H22O11 342.30 (for amorphous) 
C12H22O11_H2O 360.31 (for monohydrate) 
Description:  
 Lactose occurs as white to off-white crystalline particles or powder. It is 
odorless and slightly sweet-tasting. Spray-dried direct-compression grades of lactose 
are generally composed of 80–90% specially prepared pure a-lactose monohydrate 
along with 10–20% of amorphous lactose. 
Functional Category: 
 Binding agent; directly compressible tablet excipient; tablet and capsule 
diluents; tablet and capsule filler. 
Stability and Storage Conditions: 
 Spray-dried lactose should be stored in a well-closed container in a cool, 
dry place. 
Incompatabilities: 
 A Maillard-type condensation reaction is likely to occur between lactose 
and compounds with a primary amine group to form brown, or yellow-brown-
colored products. Lactose is also incompatible with amino acids, amfetamines and 
lisinopril. 
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Applications: 
 Lactose is widely used as a filler and diluent in tablets and capsules.  
Lactose is added to freeze-dried solutions to increase plug size and aid cohesion. 
Lactose is also used in combination with sucrose to prepare sugar-coating solutions. 
It may also be used in intravenous injections. Lactose is also used in the 
manufacture of dry powder formulations for use as aqueous film-coating solutions 
or suspensions. Direct-compression grades of lactose monohydrate are available as 
spray-dried lactose and anhydrous lactose. 
5.3  Hydroxy Propyl Methyl Cellulose:36 
Nonproprietarty names: 
 BP       :  Hypromellose 
 JP        :  Hydroxypropyl methyl cellulose 
 Ph.Eur :  Hypromellosum 
 USP     :  Hypromellose 
Synonyms: 
 Benecel MHPC; E464; hydroxypropyl methyl cellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxyl propylcellulose;   
Metolose. 
Structural formula: 
 
                                            Structure of HPMC 
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Chemical name: Cellulose hydroxypropyl methyl ether. 
Functional category: 
 Coating agent, film-former, rate-controlling polymer for sustained release, 
stabilizing agent, tablet binder, viscosity increasing agent. 
Applications  in Pharmaceutical Formulation or Technology: 
 Hypromellose is widely used in oral, ophthalmic and topical 
pharmaceutical formulations. In oral products, hypromellose is 
primarily used as a tablet binder, in film-coating, and as a matrix for 
use in extended-release tablet formulations.  
 Concentrations between 2% and 5% w/w may be used as a binder in 
either wet-or dry-granulation processes. 
 High-viscosity grades may be used to retard the release of drugs from 
the levels of 10-80%w/w in tablets and capsules. Depending upon the 
viscosity grade, concentrations of 2-20%w/w are used for film-
forming solutions to film-coat tablets. 
 Lower-viscosity grades are used in aqueous film-coating solutions, 
while higher-viscosity grades are used with organic solvents. It is 
also used as a suspending and thickening agent in topical 
formulation. 
 Hypromellose at concentrations between 0.45-1.0%w/w may be added 
as a thickening agent to vehicles for eye drops and artificial tear 
solutions. 
Description  :  HPMC is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
40 
Melting point : Browns at 190–200°C; chars at 225–230°C.Glass transition 
temperature is 170–180°C. 
Solubility:  
 Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%) and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixture of methanol and dichloromethane, and mixtures of 
water and alcohol. 
Viscosity (dynamic):  
 A wide range of viscosity types are commercially available. Aqueous 
solutions are most commonly prepared; Solutions prepared using organic solvents 
tend to be more viscous; increasing concentration also produces more viscous 
solutions. 
 To prepare an aqueous solution, it is recommended that hypromellose is 
dispersed and thoroughly hydrated in about 20–30% of their required amount of 
water. The water should be vigorously stirred and heated to 80–90°C and then the 
remaining hypromellose should be added. Then sufficient cold water should be 
added to produce the required volume. 
Table 5: Viscosity ranges of HPMC 
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Stability and storage: 
 Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11.Hypromellose powder should be stored in a 
well-closed container, in a cool, dry place. 
Incompatibilities: 
 Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts to form inso luble 
prec ip i ta tes .  
5.4  Micro Crystalline Cellulose:37 
Nonproprietary Name: 
BP      :  Microcrystalline cellulose 
JP    :  Microcrystalline cellulose 
PhEur :  Cellulosum microcristallinum 
USP :  Microcrystalline cellulose 
Synonyms: 
 Avicel PH; Celex; cellulose gel; Celphere; crystalline cellulose; E460; 
Emcocel; Ethispheres; Fibrocel; Pharmacel; abulose; Vivapur. 
Chemical Name and CAS Registry Number: Cellulose [9004-34-6] 
Empirical Formula: (C6H10O5)n where n = 220. 
Molecular weight   : 36000 
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Structural formula: 
 
 
 
 
Functional Category: 
 Adsorbent, suspending agent; tablet and capsule diluent; tablet disintegrant. 
Applications: 
 Microcrystalline cellulose is primarily as a binder/diluent  in  oral  tablet  
and  capsule formulations  where it  is used in  both  wet- granulation  and  direct-
compression processes. In addition to its used as a binder/diluent, microcrystalline 
cellulose also has some lubricant and disintegrant properties that make it useful in 
tabletting. Microcrystalline cellulose is also used in cosmetics and food product. 
Description: 
 Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. 
Typical Properties 
 Bulk density :   0.337g/cm3 
   0.32g/cm3Avicel pH-101 
 Density (tapped)  : 0.478g/cm3; 
   0.45g/cm3 for Avicel pH-101 
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  Density (true)  : 1.512–1.668 g/cm3 
 Flowability : 1.41g/s for Emcocel 90M (9)  
Moisture content: 
 Typically less than 5% w/w. However, different grades may contain 
varying amounts of water. Microcrystalline cellulose is hygroscopic. 
Stability and Storage Conditions: 
 Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities:  
 Microcrystalline cellulose is incompatible with strong oxidizing agents. 
5.5   Talc:38 
Nonproprietary Names: 
 BP       : Purified talc 
 JP        : Talc 
 PhEur  : Talc 
 USP     : Talc 
Synonyms: 
 Altalc;Hydrous magnesium calcium silicate; Hydrous magnesium silicate; 
Magsil star; Powdered talc; Purified French talc; Purtalc;  Soapstone. 
Chemical Name       :  Talc 
Empirical Formula :  Mg6 (Si2O5)4(OH)4 
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Functional Category: 
 Anticaking agent; Glidant; Tablet and capsule diluents; Tablet and capsule 
lubricant. 
Description: 
 Talc is a very fine, white-greyish, odorless, impalpable, crystalline powder. 
Moisture Content: 
 Talc absorbs insignificant amount of water at 258˚C and relative humidities 
upto about 90%. 
Storage Conditions: 
 Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
 Incompatible with quaternary ammonium compounds. 
Applications: 
 Talc was widely used in oral solid dosage formulations as a lubricant and 
diluents. It was also used as a lubricant in tablet formulations in a novel powder 
coating for extended release pellets and as an absorbant. 
5.6  Sodium Stearyl Fumarate:39 
 Nonproprietary Names:  
 BP : Sodium stearyl fumarate 
 PhEur : Natrii stearylis fumaras 
 USPNF : Sodium stearyl fumarate 
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Synonyms:  
 Fumaric acid, octadecyl ester, sodium salt; sodium monostearyl fumarate 
Chemical Name and CAS Registry Number: 
 2-Butenedioic acid, mono octadecyl ester, sodium salt [4070-80-8] 
Empirical Formula and Molecular Weight : C22H39NaO4, 390.5 
Structural formula: 
 
Functional Category: Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology: 
 It is used as a lubrication capsule and tablet formulations at 0.5–2.0% w/w 
concentration. It is also used in certain food applications. 
Description: 
 Sodium stearyl fumarate is a fine, white powder with agglomerate so flat, 
circular-shaped particles. 
Stability and Storage condition: 
 At ambient temperature, sodium stearyl fumarate is stable for upto 3years 
when stored in amber glass bottles with polyethylene screw caps. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities:  
 Sodium stearyl fumarate is reported to be incompatible with chlorhexidine 
acetate. 
5.7  Isopropyl Alcohol: 
Nonproprietary Names 
 Isopropyl Alcohol (BP, JP, PhEur, USP) 
Synonyms: 
 Alcohol isopropylicus, dimethyl carbinol, IPA, isopropanol, petrohol, 2-
propanol, sec-propyl. 
Chemical Name : Propan-2-ol 
Empirical Formula : C3H8O 
Molecular Weight : 60.1 
Structural Formula   : 
 
Description: 
 Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid 
with a characteristic, spirituous odor and it has a slightly bitter taste. 
  
47 
Typical Properties: 
 Boiling point : 82.40C 
 Flammability :  Flammable. 
 Viscosity (dynamic) : 2.43mPasat200C 
            Specific gravity           : 0.786 
Functional Category: 
 Disinfectant, solvent. 
Solubility:  
 Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and 
water. Soluble in acetone; insoluble in salt solutions. 
Applications in Pharmaceutical Formulation or Technology: 
 Isopropyl alcohol is also used as a solvent both for tablet film-coating and 
for tablet granulation, where the isopropyl alcohol is subsequently removed by 
evaporation. It has also been shown to significantly increase the skin permeability of 
nimesulide. Isopropyl alcohol has some antimicrobial activity and a 70% v/v 
aqueous solution is used as a topical disinfectant. Therapeutically, isopropyl alcohol 
has been investigated for the treatment of postoperative nausea or vomiting. 
Storage Conditions 
 Isopropyl alcohol should be stored in an airtight container in a cool, dry 
place. 
Incompatibilities 
 Incompatible with oxidizing agents such as hydrogen peroxide and nitric 
acid, which cause decomposition. 
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Safety: 
 Isopropyl alcohol is most frequently used in topical pharmaceutical 
formulations where it may act as a local irritant. When applied to the eye it can 
cause corneal burns and eye damage. 
5.8   Methylene Chloride : 
Chemical Name  :   Dichloromethane 
Other Names : Methylene chloride, methlene dichloride, narkotil, 
solaesthin. 
Appearance : Colourless liquid 
Melting point : -96.7˚C 
Taste  : Sweet aroma 
Applications: 
 DCM’s volatility and ability to dissolve a wide range of organic 
compounds makes it a useful solvent for many chemical processes. Concerns about 
its health effects have led to a search for alternatives in many of these applications. 
 Paint stripping 
 Pharmaceutical manufacturing 
 Metal cleaning 
 Paint remover 
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6. Materials and Methods 
                                  Table 6: Materials used in the study 
S.No Materials Source 
1. Felodipine Polydrug Lab Pvt Ltd, Bangalore. 
2. Lactose DCL 11 DMV ,Holland 
3. 
Hydroxy propyl Methyl Cellulose 
K100 
Rolex Chemical Industries, 
Mumbai. 
4. 
Hydroxy propyl Methyl Cellulose 
K4M 
S.D.Fine Chem.Ltd., Mumbai. 
5. Microcrystalline Cellulose pH 102 Ankit pulps chemicals pvt. 
6. Talc S.D.Fine Chemicals Ltd, Mumbai. 
7. Sodium Stearyl fumarate S.D.Fine Chemical Ltd, Mumbai. 
8. Instacoat Dow Chemicals, Canada. 
9. Methylene Chloride Lee Changyung Chemicals. 
10. Isopropyl alcohol Lee Changyung Chemicals. 
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 Table 7: Equipments used in the study 
Sl. No Equipments Manufacturers/ Suppliers 
1 Digital Weighing balance Essae,Banglore 
2 Vernier caliper (digital) Mitutoyo corps, japan 
3 Digital hardness tester Remi 
4 Friability apparatus,ET-2 Electrolab, Mumbai 
5 Tap density apparatus,ETD-1020 Electrolab,Mumbai 
6 PH meter Thermolab,Mumbai 
7 Double cone blender Vamp, Mumbai 
8 
Rotary Tablet compression 
machine, CMP210 
Elit pilot press 
9 
Dissolution test apparatus,TDT-
08L 
Electrolab,India 
10 UV-Spectrometer,UV-1601 Shimadzu, Japan 
11 HPLC Waters HPLC, India 
12 
Photostability and humidity 
chamber 
Thermolabs, Mumbai. 
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Experimental Methods 
6.1  Preformulation Studies: 
 Preformulation studies can be defined as an investigation of physical and 
chemical properties of a drug substance alone and when combined with excipient. 
Preformulation investigations are designed to identify those physiochemical 
properties and excipients that may influence the formulation design, method of 
manufacture, and pharmacokinetic-biopharmaceutical properties of the resulting 
product. It is the first step in the rational development of dosage forms. 
6.1.1  Preparation of standard calibration curve of felodipine:  
 100mg of felodipine was accurately weighed and dissolved in 25 ml 
of methanol   in 100ml volumetric flask and make up the volume using methanol, to 
make (1000 µg/ml) standard stock solution (I). Then 1ml stock solution (I) was 
taken in another 100ml volumetric flask and further dilute in 100ml of methanol to 
make (10µg/ml) standard stock solution (II), then final concentrations were prepared 
2,4,6,8, and 10 µg/ml with0.1N HCL.The absorbance of standard solution was 
determined using UV/VIS spectrophotometer at 241nm and values were shown in 
table and Fig.6 
6.1.2  Drug- Excipient Interaction Studies:40 
 The compatibility of drug and excipient is important prerequisite before 
formulation. It is therefore necessary to confirm that the drug does not react with the 
polymers and excipient under experimental conditions and affect the shelf life of 
product or any other unwanted effects on the formulation. 
 FT-IR Analysis: 
 Potassium Bromide Pellet (KBr) method was used in the study. Test 
samples were prepared by physical mixing of felodipine and exicipients in ratios of 
1:1. Initially 100mg of Potassium Bromide powder was mixed with 2mg of each 
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sample, thoroughly triturated in mortar and pestle. A portion of mixture was 
compressed using IR pelletizing press. Then the KBr pellet was placed in sample 
holder of Bruker FT-IR spectrophotometer. The spectra were recorded in the wave 
number region of 2000-500cm-1. In each case the spectra was compared with the 
pure felodipine spectrum to detect the interactions between drug and excipient. 
The FTIR Graphs of drug and excipients were shown in the Fig.7 
6.1.3  Physical properties:41 
 For a drug substance to formulate into a dosage form, it is necessary to 
study the physiochemical properties of bulk drug. 
Determination of bulk density and tapped density: 
6.1.3.1  Bulk density: 
 Bulk density is the ratio of the weight of the powder to the bulk volume it 
occupies (M).It is expressed in gm/ml. Weighed quantity of powder was transferred 
into a 50 ml measuring cylinder without tapping, during transfer the volume 
occupied by granules was measured (V0). Bulk density was measured by using 
formula. 
 Bulk density = M/Vo 
Where,  
             M = Mass of the powder 
 Vo= Volume of the powder 
6.1.3.2  Tapped Density:  
 Weighed quantity of powder was taken into graduated cylinder, volume 
occupied was noted down (M). Then cylinder was subjected to 500 taps in tapped 
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density tester (Electro Lab USP II), the final reading was denoted by (Vi).The % 
Volume variation was calculated by using the following formula. 
 Tapped density = M/Vi 
Where, 
 M = Mass of the powder  
             Vi  = Tapped volume 
6.1.3.3  Carr’s  index: 
 Compressibility is the ability of powder to decrease in volume under 
pressure. Using untapped density and tapped density the percentage compressibility 
of powder were determined, which is given as Carr’s compressibility index. 
 CI=Vi-V0 / Vi × 100 
Where,  
CI = Compressibility index             
V0 = Bulk density  
Vi   = Tapped density 
Table 8: Compressibility index 
Compressibility index (%) Flow characters 
<  10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
> 32 Very poor 
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6.1.3.4  Hausner’s ratio: 
 It is a measurement of frictional resistance of the drug. It was determined 
by the ratio of tapped density and bulk density.  
 Hausner Ratio = Vi / Vo  
Where,  
            V0   =  Bulk density 
            Vi  = Tapped density  
Table 9: Hausner ratio 
Flow characters Hausner ratio 
Excellent 1.11 
Good 1.12 – 1.18 
Fair 1.19 – 1.25 
Passable 1.26 – 1.34 
Poor 1.35 – 1.45 
Very poor 1.46 – 1.59 
Very Very poor >1.60 
 
6.1.4.5  Angle of repose: 
 Angle of Repose (θ) is the maximum angle between the surface of a pile of 
powder and horizontal plane. It is usually determined by fixed funnel method and is 
the measure the flow ability of powder. 
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Procedure: 
 A funnel was fixed to a desired height and granules were filled in it. They 
were allowed to flow down on a graph paper fixed on a horizontal surface .The 
radius was measured and angle of repose was calculated by using the formula. 
 θ = tan -1(h/r)                      
 Where,     
   θ = Angle of repose, 
 h = height of the heap of pile,  
  r = radius of base of pile. 
Table 10:  Flow Properties and Corresponding Angle of Repose 
Flow properties Angle of repose(θ) 
Excellent 25-30 
Good 31-35 
Fair – aid 36-40 
Passable 41-45 
Poor 46-55 
Very poor 56-65 
Very very poor >66 
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6.2  Formulation Development 
 The main objective of this formulation development is to design a extended 
release drug delivery system in the form of a tablet.  
Dry granulation method: 
 Felodipine extended release tablet were prepared by dry granulation 
method. 
Fig 5: Manufacturing flow chart 
Dispensing of all ingredients 
 
Shifting 
 
Drug mixing with exicipients 
 
Blending 
 
Lubrication 
 
Tablet compression 
 
Film coating 
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Procedure: 
Step 1: Weighing 
 All the ingredients were weighed accurately as per manufacturing formula  
(Table 10). 
Step 2: Shifting  
 Accurately weighed quantity of Felodipine was sifted through 30 # mesh. 
Weighed quantity of Lactose DCL11, MCC 102, HPMC K100, HPMC 
K4M was passed through 30# mesh separately. 
Step 3: Mixing  
 Felodipine was mixed with Lactose DCL11 by geometrical mixing. HPMC 
K100 and HPMC K4 M was mixed with MCC pH102 by geometrical 
mixing. 
Step 4: Shifted  
 Talc was passed through 60# mesh. Sodium stearyl fumarate was passed 
through 60# mesh. 
Step 5: Blending 
 Finally, load step3 blend into double cone blender and mixed thoroughly 
for 15 minutes.  
Step 6: Compression 
 Blended material was transferred to a tablet machine and compression 
using 27 stationed compression machine with 14/32 inch (11.11mm), 
standard concave plain on both sides. Blended material was loaded in a 
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hopper and powder was compressed to tablets by operating rotary tablet 
compression machine. 
Core tablet specifications: 
Description :  White coloured, circular shaped, slightly biconvex, uncoated   
Extended release tablet. 
Average weight (mg)      :  450± 5% 
 Hardness          :  Not Less Than 4 kg/ cm2 
 Thickness         :  4.10mm to 4.50mm 
 Friability          :  Not More Than 1.0 % 
 Assay of API    :  90%-110% 
 Dissolution (as per USP) :41 
          1st hour - 5-30% 
          4th hour - 45-70% 
          8th hour - NLT 80% 
Step 6: Film coating 
 Isopropyl alcohol was transferred into a stainless steel vessel. To 
this Instacoat was added and stirred well. 
 Finally Methylene Chloride was added under constant stirring to 
avoid lumps formation. 
 The dispersion was filtered through mesh #100. 
 The prepared tablets were coated in a coating pan till the average 
weight build up to 3% w/w. 
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Table 11: Film coating specifications 
Inlet temperature(˚c) 40-50 
Outlet temperature(˚c) 40-45 
Spray pump( rpm) 6-8 
Air pressure(kg/cm2) 4-5 
Pan (rpm) 4-8 
 
Coated tablet specifications: 
      Description: White coloured, circular shaped, slightly biconvex, film coated 
Extended release tablet 
 Average Weight (mg)       : 463.5± 5% 
  Thickness            : 4.20-4.60mm 
  Assay of API                     :  90%-110% 
 Dissolution (as per USP) :41 
            1st hour - 5-30% 
            4th hour - 45-70% 
            8th hour - NLT 80% 
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Table12: Formulation of Felodipine Extended Release tablet 
 Ingredients 
F1    
(mg) 
F2    
(mg) 
F3  
(mg) 
F4   
(mg) 
F5  
(mg) 
F6    
(mg) 
F7    
(mg) 
F8    
(mg) 
F9    
(mg) 
Felodipine 10 10 10 10 10 10 10 10 10 
Lactose DCL11 105 120 220 228 226 230.50 246 249.20 243.20 
HPMC K100 77 50 77 50 27 20.50 7 12 15 
HPMC K4M 16 12 16 14 14 12 5 7 10 
MCC 102 67 83 120 141 166 170 175 164.80 164.80 
Talc 2.5 2.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Sodiumstearyl 
Fumarate 
2.5 2.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Film coating          
Instacoat  _ _ _ _ _ _ _ _ 13.5 
Isopropyl  alcohol _ _ _ _ _ _ _ _ 105 
Methylene chloride _ _ _ _ _ _ _ _ 178 
Weight gain (%)         3% 
Total weight (mg) 280 280 450 450 450 450 450 450 463.5 
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6.3   Evaluation of Core and Film Coated Tablet  
1.  General appearance: 
 The general appearance of the tablet from each formulation batch was 
observed. 
2 .           Weight variation: 
 Twenty tablets were selected randomly from a particular batch and weighed 
individually and average weight was determined. Not more than two of the 
individual weights deviate from the average weight by more than the percentage 
deviations shown in table and none deviate by more than twice the percentage.  
Table 13: Weight variation limits (as per USP) 
 Average weight of tablet(mg) Maximum% difference allowed 
130mg or less                   10 
130-324                   7.5 
324 or more                    5 
 
3. Thickness: 
 Ten tablets from the representative sample were taken and individual tablet 
thickness was measured by using digital vernier calipers. Average thickness and 
standard deviation values were calculated. 
4. Hardness: 
 Tablet hardness was measured by using Monsanto hardness tester. From 
each batch ten tablets were measured for the hardness and average values was 
recorded. 
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5. Friability Test:  
 From each batch, 10 tablets were accurately weighed and placed in the 
friability test apparatus (Roche friabilator). Apparatus was operated at 25 rpm for 4 
minutes and tablets were observed while rotating. The tablets were dedusted and 
reweighed. The friability was calculated as the percentage weight loss. 
 % Friability was calculated as follows 
 % Friability = (W1 – W2) x 100/W1 
Where,   W1 = Initial weight of the tablets. 
  W2 = Final weight of the tablets. 
  Friability values below 1 % are generally acceptable.42 
6. Assay (as per USP):43 
Buffer solution:  
 6.9 g of monobasic sodium phosphate was accurately weighed and 
dissolved in 800 ml of water using 1000-ml volumetric flask. Adjust with 1 M 
phosphoric acid to a pH of 3.0 ± 0.05, dilute with water to volume, and mix.  
Mobile phase: 
 A filtered and degassed mixture of mobile phase was prepared. 
 Buffer solution: acetonitrile: methanol (400:400:200). 
Standard stock preparation: 
 100mg of felodipine was dissolved in 50ml of methanol using 50ml 
volumetric flask. 
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Standard preparation: 
 1ml of standard stock solution was transferred into a 100 ml volumetric 
flask and diluted upto the volume with mobile phase and mixed. 
Sample preparation: 
 Twenty tablets were weighed to obtain the average weight and were 
powdered by trituration. An accurately weighed portion of the powder, equivalent to 
10 mg of active ingredient, was mixed with 40ml of acetonitrile and 20ml of 
methanol and sonication for 5 minutes. 30ml of Buffer solution was added and 
shaked by mechanical means for 30 minutes. The solution was allowed to cool at 
room temperature and diluted with Buffer solution to the volume and mixed.10ml of 
the supernatant was transferred into a 50ml volumetric flask and diluted with mobile 
phase to the volume and mixed. The resulting solution was passed through 0.5µ 
membrane filter. 
Chromatographic system:  
Mode  :  Liquid chromatograph  
Detector  : 362-nm detector 
Column  : 4.6-mm × 15-cm column that contains packing L1.  
Flow rate  : 1 ml per minute.  
Column efficiency : Not less than 1500 theoretical plates 
Relative standard deviation for replicate injections is NMT 2.0%.  
 Injected about 10µl portion of the Standard preparation and the Assay 
preparation into the chromatograph, recorded the chromatograms, and measured the 
responses for the major peaks. 
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The% assay can be calculated by the formula: 
   Sample Area          Standard weight           dilution         Average weight     P 
  --------------------- X ----------------------- X ---------------------X -----------------X------ X 100 
  Standard Area            dilution                    sample weight              LC            100  
 
 
 
7. Invitro drug release studies:44 
 
 
Medium :  1% (w/v) polysorbate 80 in water; 500 ml.  
Apparatus  :  USP I -Basket 
RPM  :   100  
Temperature           :   37 ± 0.5˚C 
Sampling Time  :  1, 2,4, 6 and 8 hours.  
Buffer solution: 
 6.9 g of monobasic sodium phosphate was accurately weighed and 
dissolved in 400 ml of water using 1000-ml volumetric flask. Add 8.0 ml of 1 M 
phosphoric acid, diluted with water to volume, and mixed.  
Mobile phase: 
 A filtered and degassed mixture of mobile phase was prepared. 
 Buffer solution: acetonitrile: methanol (400:400:200). 
Standard stock solution: 
 Accurately 40mg of Felodipine working standard was weighed and 
transferred into a 200-ml volumetric flask, add 200 ml of methanol. Sonicate for 2 
minutes, cool, diluted with methanol to volume, and mixed.  
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Standard working solutions: 
 10ml of Standard stock solution was transferred into a 100ml volumetric 
flask, dilute with medium to volume and mixed.  
Test solution: 
 10mg tablet was transferred into a 500 ml medium. A portion of the 
solution was passed through 0.45-µm filter. Withdrawn amount was replaced with 
Medium.  
Chromatographic system: 
Mode : Liquid chromatograph  
Detector : 254-nm detector  
Column  : 4.6-mm × 15-cm column that contains packing L1. 
Flow rate : 1 ml per minute. 
Capacity factor (k ¢) : Not less than 5 
Column efficiency (N) : Not less than 1500 theoretical plates. 
Tailing factor : Not more than 1.5. 
 Relative standard deviation for replicate injections is not more than 2.0%.  
 Injected about 20 µl portion of the Standard working solution and the Test 
solution into the chromatograph, recorded the chromatograms, and measured the 
peak responses.  
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Calculation: 
 
  Sample Area            Standard weight        volume of medium       Average weight       
  --------------------- X ----------------------- X ---------------------------X --------------------X100 
  Standard Area            dilution                      sample weight                       LC                
6.4 Release kinetics: 45-48  
 The results of In-vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows. 
1. Log cumulative percent drug remaining versus time  
(first order kinetic model)  
 2.  Cumulative percent drug release versus square root of time 
(Higuchi’s model)  
3.  Cumulative percent drug release versus time  
(zero order kinetic model)        
 4. Log cumulative Percent Drug released versus log time  
(korsmeyers model)  
Drug release kinetics-model fitting of the dissolution Data: 
 Whenever a new solid dosage form is developed or produces, it is 
necessary to ensure that drug dissolution occurs in an appropriate manner. Drug 
dissolution from solid dosage forms has been described by kinetic models in which 
the dissolved amount of drug (Q) is a function of the test time, t or Q = f (t). Some 
analytical definitions of the Q (t) function are commonly used such as zero order, 
first order, Higuchi, korsmeyers-peppas models. Other release parameters, 
difference factor (f1), similarity factor (f2) can be used to characterize drug 
dissolution / release profile with the marketed product.  
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 1. Zero-order kinetics:         
 A zero-order release would be predicted by the following equation.  
               Qt    =   Qo+ Kot                     eq (1) 
Where, 
 Qt  =   amount of drug dissolved in time t 
 Qo   =  Initial amount of drug in solution 
 Kot  =  Zero-order rate constant (hr) 
                 When the data is plotted as cumulative percent drug release versus time if 
the plot is linear then the data obeys zero-order release kinetics, with a slope equal to 
ko. 
2.  First-order kinetics: 
 A first order release would be predicted by the following equation. 
                Log C    =      Log Co -  Kt / 2.303                 eq (2) 
Where 
 C    =   Amount of drug remained at time t 
 Co   =   Initial concentration of drug 
 K    =    First-order rate constant 
 The data obtained rate plotted as log cumulative percentage of drug 
remaining versus time which would yield a straight line with a slope of   ̵̵k/2.303. 
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3.  Higuchi model:  
 Drug release from the matrix devices by diffusion has been described by 
following higuchi’s classical diffusion equation. 
  Q = [DE/ τ(2A- ECs) Cst ]                       eq (3) 
Where 
Q   =   Amount of drug release at time t 
D   =   Diffusion coefficient of the drug in the matrix 
A    =   Total amount of drug in unit volume of matrix 
Cs   =    solubility of the drug in the matrix 
E     =   Porosity of the matrix 
T     =   Time in hrs at which q is the amount of drug is release 
                Equation-3 may be simplified if one assumes that D, Cs and A are 
constant.  Then equation-3 becomes 
 Q    =    Kt ½              eq (4) 
 When the data obtained were plotted as cumulative drug release versus 
Square root of time yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to k. 
4. Korsmeyers Peppas model:      
 In order to understand the mode of release of drug from swellable matrices, 
the data were fitted to the following equation   
 Mt    /    Mά         = Ktn             eq (5) 
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 Where, 
       Mt / Mά          =   fraction of drug released at time‘t’ 
       K              =   Constant incorporating the structural and geometrical 
                                    Characteristics of the drug / polymer system. 
       n              =    Diffusion exponent related to the mechanism of release. 
The above equation can be simplified by applying log on both sides we get  
 Log       Mt  /   Mά             =     Log K+ n Log t                eq (6) 
 When the data is plotted as a log of drug released versus log time, yields a 
straight line with a slope equal to n and the k can be obtained from y- intercept. 
 The value of n for a cylinder is <0.45 for fickian release, > 0.45 and < 0.89 
for non-fickian release, 0.89 for the case 2 type release and > 0.89 super case 2 type 
release. 
6.4  Similarity Factor and Differential Factor Calculation: 
 The similarity factor (f2) was defined by CDER, FDA, and EMEA as the 
“logarithmic reciprocal square root transformation of one plus the mean squared 
difference in percent dissolved between the test and marketed release profiles”. 
Dissimilarity or difference factor (f1) describes the relative error between two 
dissolution profiles. It approximates the percent error between the curves. The 
percent error is zero when the test and marketed release profiles are identical and 
increases proportionally with the dissimilarity between the two profiles. There are 
several methods for dissolution profile comparison. f2 is the simplest among those 
methods. Moore & Flanner proposed a model independent mathematical approach to 
compare the dissolution profile using two factors f1& f2. 
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  f1 = { [ ∑ t=1 nRt – Tt ] / [ ∑ t=1 nRt ] } . 100         eq (1) 
 f2 = 50. Log { [1 + (1/n) ∑ t=1 n (Rt - Tt) 2 ] –0.5 . 100}        eq (2) 
 Where 'Rt' and ‘Tt' are the cumulative percentage dissolved at each of the 
selected n time point of the marketed & test product respectively. The factor f1 is 
proportional to the average difference between the two profiles, where as factor f2 is 
inversely proportional to the averaged squared difference between the two profiles, 
with emphasis on the larger difference among all the time points. The similarity 
factor f2 and its significance is shown in the following  
Table 14: Similarity factor f2 and its significance 
S. No. Similarity factor  (f2) Significance 
1. <50 Test and Ditropan profiles are dissimilar. 
2. 50 -100 Test and Ditropan profiles are similar. 
3. 100 Test and Ditropan profiles are identical. 
4. >100 The equation yields a negative value. 
 
6.5  Stability Studies:49-51  
 Stability of a drug has been defined as the ability of a particular 
formulation, in a specific container, to remain within its physical, chemical, 
therapeutics and toxicological specifications. The purpose of stability testing is to 
provide evidence on how the quality of a drug substance or drug product varies with 
time under the influence of a variety of environmental factors such as temperature, 
humidity and light, and to establish a retest for the drug substance or a shelf life for 
the drug product and recommended storage conditions. The selected batches were 
charged on accelerated stability as per ICH guidelines.                                
71 
 Stability studies of selected formulations: 
 Stability studies were conducted for the formulation F-9 .The storage 
conditions used for stability studies were Accelerated condition 
(40°C±2°C/75%±5%RH).Sample of tablets were analyzed after 1, 2 and 3 months 
for physical characters and assay were performed followed by in vitro dissolution. 
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7. Results and Discussion 
7.1  Calibration Curve: 
Table 15: Calibration curve of felodipine 
S.No Concentration(µg/ml) Absorbance(nm) 
1 2 0.126 
2 4 0.258 
3 6 0.385 
4 8 0.508 
5 10 0.618 
 
 
 
Figure 6: Calibration curve of felodipine 
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    Fig 7: FT-IR Spectrum of Felodipine   
 
 
                           Fig 8 : FT-IR Spectrum of Felodipine + Lactose DCL 11 
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 Fig 9: FT-IR Spectrum of Felodipine+ HPMC K4M 
 
 
Fig 10: FT-IR Spectrum of Felodipine+ HPMC K100 
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Fig 10: FT- IR Spectrum of Felodipine+ MCC pH 102 
 
 
Fig 11: FT- IR Spectrum of Felodipine + Talc 
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7.2     Evaluation of granules: 
Table 16: Evaluation of granules 
Formulation 
Bulk 
density 
(g/ml)±SD 
Tapped 
density 
(g/ml) ±SD 
Hausner’s 
Ratio 
±SD 
Carr’s 
index 
±SD 
Angle of  
repose(θ) 
±SD 
F1 0.238±0.02 0.312±0.02 1.41±0.01 29.7±0.49 62.8̊±0.18 
F2 0.260±0.01 0.358±0.01 1.38±0.14 27.2±0.87 58.3̊±0.36 
F3 0.432±0.04 0.524±0.04 1.22±0.02   18.1±0.13 31.6̊±0.28 
F4 0.427±0.03 0.516±0.04 1.21±0.03   17.2±0.20 30.2̊±0.22 
F5 0.420±0.03 0.510±0.03 1.20±0.04   17.6±0.10 29.9̊±0.16 
F6 0.425±0.04 0.514±0.03 1.21±0.03   17.3±0.22 27.4̊±0.44 
F7 0.436±0.05 0.523±0.04 1.19±0.05   16.6±0.30 26.5̊±0.59 
F8 0.438±0.05 0.525±0.05 1.18±0.05   16.5±0.30 27.5̊±0.46 
F9 0.455±0.06 0.531±0.05 1.16±0.06   14.2±0.56 25.1̊±0.41 
                                                                                                             Mean±SD(n=3) 
The results show that all the formulation blends showed good flow properties and 
can form uniform tablets, except F1, F2. 
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7.3  Evaluation of Core tablet: 
Table 17: Evaluation of Core tablet 
Formulations 
Weight   
Variation 
(mg) 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
Friability               
(%) 
Drug 
content (%) 
F3 454±0.42 9.0±0.06 4.40±0.05 0.08±0.04 98.64±0.07 
F4 449±0.28 8.8±0.04 4.31±0.03 0.10±0.01 99.56±0.05 
F5 452±0.42 8.6±0.07 4.20±0.02 0.12±0.04 100.13±0.13 
F6 448±0.14 8.5±0.04 4.39±0.06 0.13±0.01 98.72±0.06 
F7 454±0.42 8.0±0.07 4.41±0.09 0.15±0.05 98.93±0.03 
F8 452±0.14 8.2±0.04 4.35±0.08 0.14±0.04 99.24±0.07 
F9 450±0.14 8.6±0.01 4.34±0.02 0.10±0.02 99.35±0.08 
Mean±SD(n=3) 
From the above post compression parameters the tablets were found to comply with 
the official standards. 
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 Fig 12: Assay Chromatogram for Standard 
 
Fig 13: Assay Chromatogram for Sample 
 
Fig 14: Dissolution Chromatogram for Standard 
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 Fig 15: Dissolution chromatogram for sample 1 hr 
 
Fig 16: Dissolution chromatogram for sample 4 hrs 
 
 
Fig 17: Dissolution chromatogram for sample 8 hrs 
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7.4  Invitro dissolution study 
Table 18: Invitro dissolution Profile for formulation (F3) 
S. No Time(hrs) 
Cumulative % drug    
release ± SD 
1 1 6.23±0.23 
2 2 11.15±0.42 
3 4 21.32±0.24 
4 6 30.57±0.45 
5 8 39.78±0.51 
  
All values are expressed as mean ± SD, n=3 
 
Fig 18 : Invitro dissolution profile for formulation F3 
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Table 19: Invitro dissolution Profile for formulation (F4) 
S.No Time (hrs) 
Cumulative % drug    
release ± SD 
1 1 10.37±0.14 
2 2 16.23±0.42 
3 4 27.65±0.45 
4 6 39.18±0.32 
5 8 53.71±0.36 
 
All values are expressed as mean ± SD, n=3 
 
Fig 19 : Invitro dissolution profile for formulation F4 
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Table 20: Invitro dissolution Profile for formulation (F5) 
S.No Time(hrs) 
Cumulative % drug      
release ± SD 
1 1 14.63±0.54 
2 2 20.28±0.49 
3 4 33.53±0.36 
4 6 46.71±0.44 
5 8 60.43±0.12 
 
All values are expressed as mean ± SD, n=3 
 
Figure 20 : Invitro dissolution Profile for formulation (F5) 
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Table 21 : Invitro dissolution profile for formulation (F6) 
S.No Time(hrs) 
Cumulative % drug      
release ± SD 
1 1 21.24±0.17 
2 2 26.89±0.46 
3 4 39.23±0.52 
4 6 54.82±0.47 
5 8 71.42±0.26 
 
All values are expressed as mean ± SD, n=3 
 
Fig 21: Invitro dissolution Profile for formulation (F6) 
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Table 22: Invitro dissolution Profile for formulation (F7) 
S.No Time(hrs) 
Cumulative % drug      
release± SD 
1 1 36.62±0.34 
2 2 48.82±0.48 
3 4 73.93±0.13 
4 6 96.87±0.40 
5 8 ̵ 
 
All values are expressed as mean ± SD, n=3 
 
Fig 22: Invitro dissolution Profile for formulation (F7) 
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Table 23: Invitro dissolution Profile for formulation (F8) 
S. No Time(hrs) 
Cumulative % drug      
release ± SD 
1 1 28.86±0.40 
2 2 40.27±0.24 
3 4 64.69±0.28 
4 6 88.72±0.32 
5 8 ̵ 
 
All values are expressed as mean ± SD, n=3 
 
Figure 23: Invitro dissolution Profile for formulation (F8) 
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Table 24: Invitro dissolution Profile for formulation (F9) 
S.No Time(hrs) 
Cumulative % drug      
release ± SD 
1 1 21.5± 0.21 
2 2 31.26±0.42 
3 4 51.94±0.36 
4 6 72.86±0.38 
5 8 92.87±0.52 
 
All values are expressed as mean ± SD, n=6 
 
Fig 24: Invitro dissolution Profile for formulation (F9) 
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Table 25: Evaluation of film Coated tablet (F9) 
Average weight(mg) 463.5 
Hardness(kg/cm2) 9.0 
Thickness (mm) 4.45 
Assay (%) 99.13 
 
Table 26: Invitro dissolution Profile for formulation (F9) film coated tablet 
S.No Time(hrs) 
Cumulative % drug      
release ±  SD 
1 1 20.11±0.24 
2 2 30.43±0.38 
3 4 51.28±0.26 
4 6 72.16±0.45 
5 8 92.07±0.44 
 
All values are expressed as mean ± SD, n=6 
  
Figure 25:Invitro dissolution Profile for formulation (F9) film coated tablet 
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 Table 27: Invitro dissolution Profile for formulation (F3-F9) & Marketed   
product  
Time 
interval 
(hrs) 
% cumulative drug release± SD 
F3 F4 F5 F6 F7 F8 F9 
Marketed 
product 
1 
6.23± 
0.23 
10.37±
0.14 
14.63±
0.54 
21.24±
0.17 
36.62±
0.34 
28.86±
0.40 
20.11±
0.24 
20.93± 
0.46 
2 
11.15±
0.42 
16.23±
0.42 
20.28±
0.49 
26.89±
0.46 
48.82±
0.48 
40.27±
0.24 
30.43±
0.38 
31.55± 
0.22 
4 
21.32±
0.24 
27.65±
0.45 
33.53±
0.36 
39.23±
0.52 
73.93±
0.13 
64.69±
0.28 
51.28±
0.26 
52.48± 
0.34 
6 
30.57±
0.45 
39.18±
0.32 
46.71±
0.44 
54.82±
0.47 
96.87±
0.40 
88.72±
0.32 
72.16±
0.45 
73.52± 
0.48 
8 
39.78±
0.51 
53.71±
0.36 
60.43±
0.12 
71.42±
0.26 
- - 
92.07±
0.44 
93.54± 
0.32 
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 Fig 26: Invitro dissolution profile for formulation (F3-F9) 
 
 
Fig 27: Comparison of optimized formulation (F9) with Marketed product 
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7.5 Release kinetics: 
Table 28: Kinetic studies of matrix Tablets 
Cumulative   
(%) release 
Time 
t 
Root t 
Log% 
release 
Log t 
Log% 
remain 
Release 
rate 
cum% 
release 
1/cum 
% 
release 
Peppas 
log 
q/100 
20.11 1 1.00 1.30 0.00 1.90 20.11 0.05 -0.70 
30.43 2 1.41 1.48 0.30 1.84 15.22 0.03 -0.52 
51.28 4 2.00 1.71 0.60 1.69 12.82 0.02 -0.29 
72.16 6 2.45 1.86 0.78 1.44 12.03 0.01 -0.14 
92.07 8 2.83 1.96 0.90 0.90 11.51 0.01 -0.04 
 
Release kinetics R2 
Zero order 0.989 
First order 0.920 
Higuchi 0.959 
Korsmeyers peppas 0.992 
 
Korsmeyers peppas Equation: 
  n = 0.719 
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7.5.1 Zero Order Kinetics: 
 
Fig 28: Graph for the formulation F8-Zero Order Kinetics 
7.5.2 First order kinetics: 
 
Fig 29: Graph for the formulation F8-First Order Kinetics 
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7.5.3 Higuchi Kinetics: 
 
Fig 30: Graph for the formulation F8-Higuchi model 
7.5.4 Korsmeyers Peppas Model: 
 
Fig 31: Graph for the formulation F8- Korsmeyers Peppas model 
 
y = 32.30x - 7.704
R² = 0.959
0
10
20
30
40
50
60
70
80
90
100
0 0.5 1 1.5 2 2.5 3
cu
m
ul
at
iv
e%
 d
ru
g 
re
le
as
e
square root of time
y = 0.719x + 1.295
R² = 0.992
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1
lo
g 
cu
m
ul
at
iv
e 
%
 d
ru
g 
re
le
as
e
log t
93 
7.6  Similarity Factor and Differential Factor:      
Table 29: Comparision between Test and Reference Product 
S.No Time(hrs) 
Cumulative % drug      
release ±  SD (test) 
Cumulative % drug      
release ±  SD 
(reference) 
1 1 20.11±0.24 20.93± 0.46 
2 2 30.43±0.38 31.55± 0.22 
3 4 51.28±0.26 52.48± 0.34 
4 6 72.16±0.45 73.52± 0.48 
5 8 92.07±0.44 93.54± 0.32 
 
Table 30: Similarity Factor and Differential Factor Calculation 
Differential Factor - F1 [ Acceptance Criteria : 0 -15] 2.19 
Similarity Factor - F2 [ Acceptance Criteria : 50-100] 90.16 
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7.7 Stability Studies: 
Table 31: Accelerated Stability Study 
Storage conditions at 40ºC ± 2˚C /75 % ± 5%RH 
Parameters Initial 1st Month 2nd Month 3rd Month 
 Description 
White colour, 
circular shape, 
slightly biconvex, 
film coated tablet 
Complies Complies Complies 
Average weight (mg) 463.5 463.5 463.4 463.2 
Thickness (mm) 4.45 4.45 4.44 4.44 
Hardness (kg/cm2) 9 9 8.9 8.9 
Assay (%) 99.13 99.08 99.02 98.93 
Dissolution 92.07 92.01 91.89 91.76 
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Discussion 
Preformulation: 
 The experimental work started with the raw material analysis of felodipine 
as per USP, the physical properties such as bulk density, tapped density, Carr’s 
index, Hausner’s ratio and angle of repose values were depicted in the Table: 16 
Calibration curve:  
 The calibration curve of Felodipine was prepared in 0.1N HCL at 
determined wavelength at 241nm. The r2 and slope were found to be 0.9946 and 
0.0628.The results were shown in Table 15 and Fig: 6 
FT-IR Studies: 
 The IR spectra of pure drug showed sharp peaks at 1689cm-1 for C=O 
Ester,1643 cm-1 for NH Bending, 1642,1496 cm-1 for -C=C Stretching,1099 cm-1 for 
–C-O-C, 790cm-1for Benzene ring Stretching,567cm-1for C-Cl for Stretching. These 
peaks were found to be prominent in the spectra of physical mixtures containing the 
drug and excipients. This indicates there was no interaction between drug and 
excipients shown in the Fig: 7-13. 
Evaluation of Physical Mixture: 
 Bulk density, Tapped density, Carr’s index, &Hausner’s ratio, Angle of 
repose were evaluated for the prepared blend. 
 Formulations blend F1 and F2, the angle of repose was found to be 58.3̊ and 
62.8̊. It shows very poor flow property because diluent and disintegrant concentration was 
low to their average weight. Bulk density, Tapped density, Carr’s index and Hausner’s 
ratio was not within the limits. Carr’s index was found to be 29.7 and 27.2. 
Hausner’s ratio was found to be 1.41 and 1.38.From this it indicates that the 
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formulation F1 and F2 have poor flow property and also not suitable for 
compression. 
 From the formulations F3 to F9, to improve the flow property, diluent and 
disintegration concentration was increased, it shows good flow property. The angle of 
repose was found to be in the range 25.1̊ to 31.6˚.Compressibility index  was carried 
out, it found between14.2 to 18.1,  indicating the powder blend has the required flow 
property for compression. Hausner’s ratio was calculated for the blend, it was found 
to be 1.16-1.22. The results showed in the Table: 16 
Evaluation of Core Tablet: 
 The results were shown in the Table: 17. The hardness of tablets of each 
batch ranged between 8 to 9 kg/cm2, this ensures good handling characteristics of 
all batches. Thickness of all the formulation was found to be in the range 4.20mm to 
4.40mm. All the formulations were found to be in the range 0.08% to 0.15%.The 
percentage of drug content for F3 to F9 was found to be 98.64% to 100.13%, it 
complies with official specifications. 
Effect of HPMC K100 and HPMC K4M on drug release: 
 All the formulations were prepared by dry granulation technique. Different 
formulations were developed using different concentration of polymer. Basically, 
HPMC is a hydrophilic polymer which controls the release rate of the drug for the 
extended period of time. For the formulation F3 containing 17% of HPMCK100 and 
4% of HPMC K4M, the release from the formulations were found to be 39% at the 
end of 8th hour which shows the release was not within the USP specification limit. 
As the polymer concentration was high, the drug release shows poor. The results 
were shown in the Table 18 and Fig 19. 
 For the formulation F4 the polymer concentration was reduced to 11% of 
HPMC K100 and 3% of HPMC K4M, the drug release were found to be 53.71% 
which are not within the specified limits, but the release was improved compared to 
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F3,the concentration of polymer was high which provides the slow release of drug, it 
was further reduced. The results were shown in the Table19 and Fig 20. 
 Formulation F5 HPMC K100 was reduced to 6% and HPMC K4M was 
kept at same concentration, the release was found to be60%, because HPMC K4M, a 
high viscosity grade was more, it was reduced to the next formulation. The results 
were shown in the Table 20 and Fig 21. 
 Formulations F6, the polymer was reduced to 4.5% of HPMC K100 and 
2.5% of HPMC K4M shows the release 72% at the end of 8 hours which was not 
within the USP limits. The results were shown in the Table 21 and Fig 22. 
 Hence to meet the required release profile, polymer concentration was 
further reduced for the formulation F7 (1.5% of HPMC K100 and 1% of HPMC 
K4M), 97% of the drug was released at the end of 6 hours. The results show the 
drug was not released for extended period of time because of their low polymer 
concentration. Therefore, the polymer concentration was increased for next trial. 
The results were shown in the Table 22and Fig 23. 
 Formulation F8 containing 2.5% of HPMC K100 and 1.5% of HPMC 
K4M, which shows 89% of the drug was released at the end of 6 hours. 
Furthermore, the polymer concentration was increased to the next trial. The results 
were shown in the Table 23 and Fig 24. 
 Finally, the release from the formulation F9 containing 3% of HPMC K100 
and 2 % of HPMC K4M at 1st,4th,8th was found to be 21.5%, 51.94%, 92.87% which 
was within the USP limits. The results were shown in the Table 24 and Fig 25. 
 When the concentration of polymer was increased, the drug release was 
found to be decreased. The type and concentration of polymer influenced the rate 
and release of the drug. Therefore, from formulations F3 to F9 different 
concentration of HPMC K100 and HPMC K4M showed different release profiles, of 
these formulations F9was observed to be followed USP specifications for extended 
release tablets. 
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Interpretation of Dissolution Profile: 
 The results of dissolution studies indicate that the release was influenced by 
the viscosity grade of polymers. The polymer HPMC K100, HPMC K4M had a 
retarding effect with high concentration. When the polymer concentration is high, 
the drug release was found to be slow. Once there is a sufficient polymer 
concentration is achieved in the core of the tablet or in the matrix system, upon 
dissolution a uniform layer is formed to protect the drug release immediately into 
the dissolution medium. According to this only the formulation F9 followed the 
desired release profile upto 8th hour, as per the requirement of US Pharmacopoeia. 
Evaluation of film coated tablet: 
 The optimized formulation F9 was observed. The results were shown in the 
Table 26 and Fig 26. The thickness was found to be in the range 4.45mm. The 
hardness was found to be 9 kg/cm2. The percentage of drug content was 
99.13%.Optimized formulation F9, the drug release was found to be 20.11%, 
51.28% and 92.07 % at the end of 1st,4th and 8th hour which was within the USP 
limit. Formulation F9 shows the similar release profile to marketed product.  
Release kinetic study for optimized matrix tablet: 
 Dissolution data of the optimized formulation was fitted to various kinetic 
model (zero order, first order, Higuchi and korsmeyers peppas) in order to describe 
the drug release profile. The plot of cumulative percentage drug release as a function 
of time indicates that none of the formulation follows first order or Higuchi Kinetics 
(Table: 28) the line of best fit obtained was zero order release kinetics (R2=0.989) 
and Korsmeyers Peppas model, the drug release data further analyzed for curve 
fitting and the results (n=0.719) confirmed that the formulation follows non–fickian 
(anomalous) diffusion kinetics. 
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Comparision between Optimized batch and Marketed product: 
 The optimized formulation F9 was compared to the marketed product. In 
optimized formulation, the drug release was found to be20.11%, 51.28%, 92.07% at 
the end of 1st,4th and 8th hour was seemed to be close to the marketed product, the 
drug release was found to be 20.93%, 52.48% and 93.52%. Similarity factor( f2) and 
dissimilarity factor(f1) was calculated between F9 and marketed product. 
Differential factor (f1) and Similarity factor (f2) was found to be 2.19 and 90.16, 
which shows similar release profile to the marketed product. The results were shown 
in the Table 30. 
Stability batch: 
 Stability studies were conducted for the formulations F9. The stability 
study was performed at 40ºC /75 % RH/ 3 months. The tablets were analyzed for 
appearance, average weight, thickness, hardness, drug content and in vitro drug 
release. The overall results showed that the formulation is stable at the above 
mentioned Storage conditions the results were depicted in Table: 31 
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8. Summary 
 In the present study an attempt was made to prepare Felodipine Extended 
release tablet for the treatment of hypertension. 
Chapter 1- begins with a general introduction presenting an overview of about 
extended release drug delivery systems. In the part of introduction the advantages, 
disadvantages, mechanism of extended release systems and matrix tablets were 
discussed thoroughly. 
Chapter2- described the literature related to this work was surveyed and a brief 
discussion had been given on each literature. 
Chapter 3 - detailed the aim and objective of the present study. 
Chapter 4- described the plan of the work. 
Chapter 5 -gives information on the selection of drugs and excipients; thereby 
felodipine is suitable candidate for extended release dosage form.  
Chapter 6-deals with the materials and methods used in the present study was 
given. This chapter covers the details of the experimental methods including 
evaluation of the core and film tablets, evaluation of physical mixture and also about 
release kinetics. 
Chapter 7- Includes the results and detailed discussion of all the formulations, all 
the qualitative and quantitative parameters were analyzed and tabulated. The drug 
excipient compatibility study was done and found to have no interactions. 
 Pre-compression parameters of the prepared tablets (Bulk density, Tapped 
density, Carrs index and Angle of repose) are in the range of given in official 
standard, indicates that the physical mixture were found to be free flowing. Invitro 
dissolution studies were done for Felodipine Extended release tablet prepared with 
different concentration of polymer HPMC K100 low viscosity grade and HPMC 
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K4M high viscosity grade. Formulation F9 was found to be 92.07% drug release at 
the end of 8th hours which was within the USP limits. 
 The kinetic of drug release for formulation F9 was calculated and plotted. 
The formulation F9 follows zero order release kinetics and the drug release 
mechanism was found to be non-fickian (anomalous) diffusion. The optimized 
formulation was compared with marketed product and showed similar release 
profile. 
 The optimized tablets F9 were selected for stability studies were carried out 
according to ICH guidelines at 40ºC /75 % RH for a specific time period indicated 
that the physical parameters and drug release characteristics were not altered 
significantly showing good stability on storage. 
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9. Conclusion 
 Felodipine is widely used an anti hypertensive agent. It is formulated as an 
extended release tablet, which shows better patient compliance and reduces side 
effects. Based on various studies carried out we have arrived at following 
conclusions. 
 Extended release matrix tablet of Felodipine 10mg prepared by dry 
granulation technique. Various polymers with various concentrations were 
developed and evaluated. The formulation containing 3% of HPMC K100 and 2% of 
HPMC K4M (F9 batch) followed the desired release profile and selected for further 
studies. The optimized formulation follows zero order release pattern and the drug 
release mechanism was non-fickian (anomalous transfer).The optimized formulation 
F9 and the marketed formulation were found to have a similar invitro release profile, 
which is confirmed by f1 and f2 values. 
 Therefore, erosion and diffusion mechanism found to be responsible for 
extended release of felodipine from formulated matrix tablet. The formulation (F9) 
found to be stable under accelerated conditions for 3 months with respect to physical 
characteristics and drug content. However, the in vivo pharmacokinetic studies are 
required to confirm these results. 
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